Tekla Capital Management LLC increased its holdings in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 42.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 171,889 shares of the biopharmaceutical company’s stock after purchasing an additional 51,377 shares during the quarter. Tekla Capital Management LLC owned approximately 0.17% of Sangamo Therapeutics worth $2,914,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. United Services Automobile Association lifted its stake in Sangamo Therapeutics by 9.2% during the second quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock worth $818,000 after purchasing an additional 4,860 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Sangamo Therapeutics by 42.2% during the second quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock worth $11,218,000 after purchasing an additional 234,346 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Sangamo Therapeutics by 14.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 565,601 shares of the biopharmaceutical company’s stock worth $8,032,000 after purchasing an additional 71,134 shares during the last quarter. Northern Trust Corp lifted its stake in Sangamo Therapeutics by 21.0% during the second quarter. Northern Trust Corp now owns 1,287,800 shares of the biopharmaceutical company’s stock worth $18,286,000 after purchasing an additional 223,870 shares during the last quarter. Finally, Platinum Investment Management Ltd. purchased a new stake in Sangamo Therapeutics during the second quarter worth approximately $751,000. Hedge funds and other institutional investors own 63.13% of the company’s stock.
In other news, VP Edward R. Conner sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $14.17, for a total transaction of $70,850.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director H Stewart Parker purchased 2,000 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were bought at an average price of $13.52 per share, with a total value of $27,040.00. The disclosure for this purchase can be found here. In the last quarter, insiders sold 30,000 shares of company stock valued at $405,400. 1.20% of the stock is owned by company insiders.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. Sangamo Therapeutics had a negative return on equity of 22.06% and a negative net margin of 88.78%. The company had revenue of $23.56 million during the quarter, compared to analysts’ expectations of $26.96 million. During the same quarter in the previous year, the business earned ($0.15) earnings per share. The firm’s revenue for the quarter was up 99.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Sangamo Therapeutics Inc will post -0.72 earnings per share for the current year.
Several equities research analysts recently weighed in on SGMO shares. Wedbush restated a “hold” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, August 9th. BidaskClub upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. Finally, Guggenheim initiated coverage on Sangamo Therapeutics in a research note on Tuesday, October 9th. They issued a “buy” rating and a $18.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $19.71.
TRADEMARK VIOLATION NOTICE: This article was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2018/12/04/sangamo-therapeutics-inc-sgmo-position-raised-by-tekla-capital-management-llc.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Featured Article: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.